Compare · SRPT vs XCUR
SRPT vs XCUR
Side-by-side comparison of Sarepta Therapeutics Inc. (SRPT) and Exicure Inc. (XCUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SRPT and XCUR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- SRPT is the larger of the two at $1.52B, about 236.9x XCUR ($6.4M).
- SRPT has been more active in the news (8 items in the past 4 weeks vs 5 for XCUR).
- SRPT has more recent analyst coverage (25 ratings vs 2 for XCUR).
- Company
- Sarepta Therapeutics Inc.
- Exicure Inc.
- Price
- -
- -
- Market cap
- $1.52B
- $6.4M
- 1M return
- -23.76%
- -
- 1Y return
- -14.03%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 8
- 5
- Recent ratings
- 25
- 2
Sarepta Therapeutics Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Exicure Inc.
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNAÂbased therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.
Latest SRPT
- SEC Form 13F-HR filed by Sarepta Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Sarepta Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Sarepta Therapeutics Inc.
- Sarepta Therapeutics upgraded by Deutsche Bank with a new price target
- Sarepta Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments
- SEC Form 10-Q filed by Sarepta Therapeutics Inc.
- Sarepta Therapeutics to Present at Upcoming Investor Conferences
- Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
- Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
Latest XCUR
- Exicure Announces Filing of Notification of Late Filing on Form 12b-25
- SEC Form DEF 14A filed by Exicure Inc.
- Exicure Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion
- SEC Form PRE 14A filed by Exicure Inc.
- Exicure Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement
- SEC Form 10-Q filed by Exicure Inc.
- Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
- Large owner Exicure Hitron Inc. acquired $2,804,738 worth of Common (623,275 units at $4.50), increasing direct ownership by 39% to 2,222,224 units (SEC Form 4)